
Therapeutics Issue of Evidence-Based Diabetes Management Takes on Cost, Coverage, and Combinations
Whether it’s the high cost of insulin or the question of when to start combination therapy, the new issue of Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care, covers up-to-the-minute topics in this special issue on therapeutics. Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, leads off this issue featuring voices of providers, pharmaceutical leaders, payers, and patients.
FOR IMMEDIATE RELEASESeptember 27, 2016
PLAINSBORO, N.J.—Questions that have experts in other diseases for years are reaching stakeholders in one of the fastest growing conditions on the planet—diabetes. In its new issue, Evidence-Based Diabetes Management addresses the promise and challenges of new therapies for a condition that affects more than 29 million people in the United States.
Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, the chief medical officer of Joslin Diabetes Center starts the discussion with his
“As our colleagues who treat cancer and rare diseases have understood for years, nobody’s completely guilty, but nobody’s completely innocent either, which makes solutions challenging,” Gabbay says.
Highlights of the issue include:
· A must-read
· An original
· An account of high expectations for competing
· Coverage of recent Peer Exchanges, in which experts discussed new cardiovascular outcomes research on empagliflozin, and the opportunities for more patients with diabetic macular edema to benefit from modern therapies.
About the Journals and AJMC.com
The American Journal of Managed Care is the leading peer-reviewed journal dedicated to issues in managed care.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.